A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Abituzumab (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Acronyms STRATUS
- Sponsors EMD Serono
- 27 Jul 2017 Planned End Date changed from 31 Oct 2020 to 17 Dec 2019.
- 09 Aug 2016 Status changed from not yet recruiting to recruiting.
- 25 Jul 2016 New source identified and integrated (United Kingdom Clinical Research Network; 30989).